Top Health Tools
Top Health Tools

Top Reports
Top Reports
 
Top Articles
Top Articles

Top Reviews
Top Reviews
   
Letter Released From FDA Fabricates
H1N1 Vaccine Safety and Effectiveness

The Food and Drug Administration (FDA) Commissioner has released a letter to U.S. healthcare professionals which attempts to restore confidence in the H1N1 vaccine, while making outlandish claims on the vaccine's safety and effectiveness.

For clarity, bold faced excerpts of the Commissioner's letter will be emphasized below. An explanation of each misrepresentation of the facts will follow:

As this new infectious disease sweeps through communities across the country, you must juggle your usual patient care responsibilities with a special role in influenza response. Delays in vaccine delivery and the persistence of myths about vaccination have not made your job any easier. Thank you for rising to this public health challenge.

The only delays in vaccine delivery have been caused by the deliberate attempts by government to create artificial scarcity and the usage of shortage marketing techniques to foster a sense of urgency and panic. It's similar to the "Hot Christmas Toy Phenomenon" where toys are stocked to the max in a warehouse and toy companies create scarcity so people frantically run to the store and take them off the shelves.

The only myths portrayed by the mainstream media are actually facts and vice-versa. Common myths that the media portrays as facts are that flu vaccines prevent the flu, create immunity, are non-toxic and proven safe and effective. All are complete fallacies.

The Commissioner then goes through a ludicrous explanation to justify how the 2009 H1N1 vaccine is made in an attempt to validate the six month manufacture-to-delivery time frame:

Some of your patients may be asking how the FDA, the manufacturers, and the scientific community can have confidence in vaccines that were available just six months after the 2009 H1N1 virus emerged.

...scientists at laboratories in the United States and elsewhere modified the 2009 H1N1 virus into a version suitable to be used as the “seed” for the development of vaccines.... For the 2009 H1N1 virus, modified strains suitable for vaccine manufacturing were created and provided to influenza vaccine manufacturers by late May.

...next step was to develop a tool to accurately measure the amount of vaccine antigen that was being produced. Scientists from the United States, United Kingdom, Australia, Japan, and other nations, working together as part of the World Health Organization, developed the reagents needed to assure the proper amount of antigen goes into each dose of vaccine.

Anybody who has worked extensively in the vaccine industry can attest to the minimum 3-5 year (sometimes 7-10) turnaround period from initial manufacture and development to delivery. The modified strains were NOT created and provided to vaccine manufacturers in late May as the Commissioner suggests. The only way this vaccine could have been produced this quickly, was if they knew about it in 2006 or before. Well, IBM knew about it, perhaps all the vaccine manufacturers did as well. After all, Novartis' patent application was in 2006.

As previously reported, the standard to test any vaccine is to first produce exposure to the virus and subsequently prevent the infection. This is the only scientifically established method of concluding the efficacy of any vaccine. What the Commissioner fails to address in her unscientific rhetoric, is that because of the speedy regulatory approvals that were necessary to get these pandemic vaccines on the shelf, it would have been virtually impossible for any manufacturer or laboratory to effectively test any of these H1N1 vaccines using this protocol. Influenza vaccines (including H1N1) have actually never used the protocol to begin with. Thus, every H1N1 vaccine manufactured and claimed to be tested has been approved using scientific fraud!

In fact, most H1N1 vaccines trials are still ongoing and no conclusive results have been generated for any of them. A simple search at clinicaltrials.gov will validate this fact.

We are not cutting any corners. Just as for seasonal influenza vaccine, no lot of the 2009 H1N1 vaccine can be used until it has been carefully evaluated and released as sterile and potent by both the manufacturer and by the FDA.

In addition, the FDA and other agencies are looking for any unexpected, rare, serious adverse events and are quickly investigating concerns. We are also collaborating with our global counterparts to share information and experience. Should any safety concerns arise, we will evaluate them thoroughly and bring them to the public’s attention quickly.

The entire U.S. population is being used as a giant experiment with vaccines that have not even passed trials as evidenced through inconclusive and ongoing trials.

How have they proven safety and effectiveness? How have they not cut corners? How have they carefully evaluated the vaccine?

Every single ingredient in the H1N1 vaccine approved for use in the U.S. from Sanofi-Pasteur, Novartis, MedImmune to CSL contain carcinogenic, neurotoxin, immuntoxin and sterile agents. No pharmacokinetic properties have been studied for any of these toxins and their effects in any of the above "approved" H1N1 vaccines is unknown according to all vaccine inserts.

It would be impossible to generate any more lies than are already listed in this address to health professionals. The FDA Commissioner, Margaret Hamburg, should revise her letter to at least contain one truth because as it stands, this story makes Harry Potter look factual.

Dave Mihalovic is a Naturopathic Doctor who specializes in vaccine research, cancer prevention and a natural approach to treatment.


Reference Source FDA.gov
November 13, 2009

Share/Bookmark
...............................................................................................................

This site is owned and operated by PreventDisease.com 1999-2014. All Rights Reserved. All content on this site may be copied, without permission, whether reproduced digitally or in print, provided copyright, reference and source information are intact and use is strictly for not-for-profit purposes. Please review our copyright policy for full details.
aaa
Interact
volunteerDonateWrite For Us
Stay Connected With Our Newsletter